2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Machine Learning, Natural Language Processing, Biological Processes, Pathogenesis, Genomics, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Study Population, Human, Adult, Young Adult
PAPER

3881 Real-world treatment patterns and class-specific outcomes after covalent BTK inhibitor and venetoclax exposure in chronic lymphocytic leukemia

Yumeng Zhang, MD, Supreet Kaur, MD2, Mohammad Ammad Ud Din, MD3, Daniel DeAvila Jr, M.S.4, Michael D. Jain, MD, PhD5, Nima Ghalehsari, MD6, Celeste Bello, MD7, Leidy Isenalumhe, MD, MS8, Bijal Shah, MD, MS9, Sameh Gaballa, MD10, Lubomir Sokol, MD, PhD11, Javier Pinilla-Ibarz, MD PhD12
1 Moffitt Cancer Center, Tampa, Florida, United States
2 Moffitt Cancer Center, Tampa, Florida, United States
3 Avera Medical Group Hematology, Transplant & Cellular Therapy, Sioux Falls, South Dakota, United States
4 Moffitt Cancer Center, Tampa, Florida, United States
5 Moffitt Cancer Center, Tampa, Florida, United States
6 Moffitt Cancer Center, Tampa, Florida, United States
7 Moffitt Cancer Center, Tampa, Florida, United States
8 Moffitt Cancer Center, Tampa, Florida, United States
9 Moffitt Cancer Center, Tampa, Florida, United States
10 Moffitt Cancer Center, Tampa, Florida, United States
11 Moffitt Cancer Center, Tampa, Florida, United States
12 Moffitt Cancer Center, Tampa, Florida, United States

Background. Options after exposure to both a covalent BTK inhibitor (cBTKi) and venetoclax have expanded rapidly: a noncovalent BTK inhibitor and lisocabtagene maraleucel (liso-cel) are approved and BTK degraders are in development, shifting the question from whether treatment exists to which class to select. Prior real-world cohorts have described treatment patterns; class-specific depth of response remains incompletely characterized, and cross-trial comparison is limited by differences in populations, prior therapies and endpoints.

Methods. We identified all consecutive adult patients (pts) with CLL/SLL at a single center exposed to both a cBTKi and venetoclax. Pts were classified as double-refractory (DR: progressive disease [PD] on both classes, with histologic transformation on an active drug counted as a PD event) or double-exposed (DE: discontinuation of at least one class for a reason other than PD). The DR landmark was the start of the first therapy initiated for the qualifying event, or the event date if none followed; the DE landmark was discontinuation of the second class. Data cutoff was 30 June 2026. The primary analysis used each pt's first treatment episode per class (one observation per pt per class). The endpoint was time to next treatment or death (TTNT-D), applied consistently across all classes including CAR-T. Responses were abstracted from clinician documentation using iwCLL criteria for CLL and lymphoma criteria for transformed disease; Richter-directed regimens are reported separately, and CAR-T was restricted to commercial autologous CD19 products, reported by product. Analyses were descriptive; classes were not compared inferentially.

Results. Of 1,255 records screened, 167 pts had exposure to both classes (42 DR, 125 DE); 133 (42 DR, 91 DE) entered the landmark analysis, 34 DE pts being excluded as they remained on the second class. Landmarks ranged from September 2016 to February 2026. Double exposure occurred a median of 9.4 years after diagnosis, following 5 prior lines in DR and 4 in DE; median follow-up 33.7 and 34.0 months. DR was enriched for TP53 aberration at diagnosis (72% vs 48%) and ever-detected BTK variants (45% vs 16%; p<0.001), including C481 variants (31% vs 9%; p=0.001).

DR pts had greater post-landmark treatment utilization: 5% received no further therapy versus 44% of DE, and 76% received at least 2 subsequent lines versus 30%. The most-utilized DR classes were noncovalent BTKi-based therapy (45%), cBTKi switching or re-exposure (26%), commercial CD19 CAR-T (26%) and Richter-directed therapy (26%); in DE the most-utilized class was cBTKi-based therapy (24%), predominantly a switch from ibrutinib to a second-generation agent.

In DR, noncovalent BTKi-based therapy included 19 pts, with responses in 9 of 18 evaluable (50%; 95% CI, 26-74) and median TTNT-D 8.5 months. Among 10 evaluable pts on single-agent pirtobrutinib, 5 responded (50%; 19-81) but no complete responses occurred (0/10; 0-31). Across all BTKi-based salvage classes, no complete response was documented among 57 evaluable pts (0%; 0-6).

Five DR pts received liso-cel followed by maintenance pirtobrutinib; 4 responded (80%; 28-99) including 3 complete responses (60%; 15-95), median TTNT-D not reached with 80% free of next treatment or death at 12 months (median follow-up 9.3 months). Among 6 DR pts given other commercial CD19 products, ORR was 33% and CR 17%.

In DE, cBTKi-containing therapy (n=22, 20 evaluable) gave median TTNT-D 20.0 months (95% CI, 6.1-NE) and ORR 30% (12-54). Liso-cel (n=6) achieved an ORR of 83% (36-100) with CR in 50% (12-88).

Eleven DR pts (26%) received Richter-directed therapy (ORR 50%; TTNT-D 2.9 months). OS at 36 months was 30% in DR versus 60% in DE. Of 64 deaths, 48% were attributable to progressive CLL and 20% to Richter’s; 5% were treatment-related.

Conclusions. After exposure to both a cBTKi and venetoclax, DR pts had substantial ongoing treatment needs. Noncovalent BTKi-based therapy produced responses in approximately half of evaluable pts but no complete responses. Commercial autologous CD19 CAR-T achieved the deepest observed responses, and the 5 DR pts given liso-cel followed by maintenance pirtobrutinib had favorable observed outcomes. Subsequent cBTKi-containing therapy had limited activity in DR, while outcomes in DE reflected heterogeneous treatment contexts. Richter transformation remained a major unmet need, accounting for 26% of DR salvage treatment and 20% of total deaths.

Yumeng Zhang, MD: Curio Science - Honoraria; Plexus Communications - Honoraria; Acrotech Biopharma - Consultancy (Includes expert testimony); Citius Oncology - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Arima Genomics - Consultancy (Includes expert testimony); Kyowa Hakko Kirin Pharma, Inc. - Consultancy (Includes expert testimony); AbbVie, Inc. - Consultancy (Includes expert testimony)